Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo and Its Autotaxin Inhibitor (PAT-409)
South San Francisco, CA – September 25, 2019 – Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, a Phase I ready autotaxin inhibitor for patients with fibrotic diseases.
“With the addition of this IND enabled program to our pipeline, we advance our agenda to bring innovative treatments to patients with fibrotic disorders,” stated Wendye Robbins, M.D., Blade’s President and Chief Executive Officer. “Autotaxin inhibition offers a distinct but complementary anti-fibrotic mechanism to our lead program, BLD-2660, a calpain inhibitor. We believe our two anti-fibrosis programs will each succeed as standalone therapies and potentially serve as elements for combination treatment.”
PAT-409 inhibits all the autotaxin isoforms, which are the enzymes responsible for generating most extracellular lysophosphatidic acid (LPA), and thereby attenuates the fibrosis process. In addition, PAT-409 reveals key gene expression differences relative to other clinical autotaxin inhibitors that we expect to drive a differentiated profile for this drug. The autotaxin/LPA receptor pathway has been clinically validated in patients with idiopathic pulmonary fibrosis. In multiple preclinical models, and across various tissues and organs, PAT-409 demonstrated robust ability to reduce tissue damage and fibrosis.
“As ATXCo evaluated opportunities for PAT-409, it became clear that Blade’s commitment to patients with fibrosis and best-in-class team provide an excellent vehicle for its future development,” said Robert Williamson, ATXCo’s President and Chief Executive Officer.
“With the addition of PAT-409, Blade anticipates having three active clinical programs in the near-term, including two orthogonal approaches aimed at fibrosis,” added Dr. Felix Karim, Blade’s Executive Vice President of Business Development. “We look forward to generating both single agent and combination data in a variety of disease settings.”
About Blade Therapeutics
Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade’s lead compound, BLD-2660, is a highly selective calpain inhibitor targeted for the treatment of chronic fibrotic diseases. BLD-2660 is in a Phase I, healthy volunteer, dose escalation study in Australia, and the Company plans to submit an Investigational New Drug (IND) application to the U.S. FDA and initiate a Phase II trial in patients with liver fibrosis by year-end 2019. Blade has assembled a critical mass of anti-fibrotic drug development expertise within its top-tier leadership team and a world-class network of advisors. Lead investors in Blade include MPM Capital, Deerfield, Pfizer Ventures, One Ventures, Osage Partners, Bristol-Myers Squibb and Novartis Institute of Biomedical Research. Please visit https://www.blademed.com/ for more information.
About ATXCo, Inc.
ATXCo’s core asset is PAT-409, a Phase I ready autotaxin inhibitor for idiopathic pulmonary fibrosis (IPF), NASH (nonalcoholic steatohepatitis), PBC (primary biliary cholangitis), scleroderma and chronic kidney disease. ATXCo key shareholders include Bay City Capital and Celgene Corporation.
Contacts
Blade Therapeutics
Wendye Robbins, M.D., President and CEO
wrobbins@blademed.com
ATXCo
Robert Williamson, President and CEO
RobW@LaSalleAdvisers.com
Burns McClellan
Cameron Radinovic
Blade@burnsmc.com
212.213.0006